Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy

CompletedOBSERVATIONAL
Enrollment

330

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

November 13, 2024

Study Completion Date

December 1, 2024

Conditions
Cardiomyopathies
Interventions
DIAGNOSTIC_TEST

Magnetocardiography scan

The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.

Trial Locations (1)

12203

Deutsches Herzzentrum der Charité, Steglitz

Sponsors
All Listed Sponsors
collaborator

Berlin Institute of Health at Charité

UNKNOWN

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

Biomagnetik Park Holding GmbH

UNKNOWN

lead

German Heart Institute

OTHER

NCT06689098 - Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy | Biotech Hunter | Biotech Hunter